A stealthy Silverback Therapeutics has been building up its C-suite with top talent from a pair of high profile biotechs in the Seattle area.
GeekWire reported over the weekend that Silverback recruited Seattle Genetics $SGEN COO Eric Dobmeier to take the helm at Silverback. Seattle Genetics reported Dobmeier’s planned departure in an SEC filing on Friday.
Orbimed’s Peter Thompson came in with a $10 million ante to a $60 million launch round last year, paving the way to recruiting Seattle Genetics’ VP of manufacturing Mike Sun. And the tech wire service added that Juno contributed Sam Blackman, a senior medical director at the I/O company, as head of clinical development while Valerie Odegard stepped over to become SVP of research.
Nobody’s saying right now what the biotech upstart will be doing, but based on the resumes of everyone involved so far, it would seem a safe bet that immunotherapy — the current darling of cancer R&D — is playing a big role.
The latest hire marks a big change for Seattle Genetics, where Dobmeier had worked for the past 16 years with CEO Clay Siegall, who’s had to wrestle with his share of setbacks over the past year.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.Free Subscription